Physician profile
Christopher Hill Crabtree
NPI 1265472963
$11,200.05
in general payments reported to CMS, 2019-2025
30 companies · $2,813 in 2025
The $2,813 reported for 2025 was more than what 96% of Foot Surgery providers received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,663 · 2020: $174 · 2021: $1,572 · 2022: $919 · 2023: $3,257 · 2024: $801 · 2025: $2,813.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,805 · Food and Beverage: $3,067.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,805.44 |
| Food and Beverage | $3,066.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Peerless Surgical INC. | $3,070.03 | 2020-2025 | |
| Medical Device Business Services, INC. | $2,861.81 | 2019-2025 | Na, Motoband |
| Stryker Corporation | $1,284.38 | 2019-2025 | Prostep, Swanson, Lmh |
| Arthrex, INC. | $1,180.56 | 2023-2025 | |
| Convatec INC. | $721.79 | 2023-2025 | |
| Depuy Synthes Sales INC. | $693.80 | 2019-2025 | Motoband, Fibulink, Minibunion |
| Organogenesis INC. | $153.09 | 2021 | |
| Horizon Therapeutics Plc | $144.81 | 2019-2022 | |
| Epsfl, LLC | $138.01 | 2023 | |
| Paratek Pharmaceuticals, INC. | $129.70 | 2022-2025 | Nuzyra |
| Sebela Pharmaceuticals INC. | $98.83 | 2019-2023 | Naftin |
| Smith+Nephew, INC. | $92.69 | 2022-2024 | Renasys Go V2 Home, Grafix Pl, Collagenase Santyl |
| Kerecis Limited | $77.35 | 2019-2022 | |
| Bioventus LLC | $65.02 | 2023-2025 | Exogen Ultrasound Bone Healing System, Exogen Ultrasound Bone Healing System |
| Progenacare Global, LLC | $58.97 | 2024 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sandoz INC. | $56.01 | 2019-2020 | |
| Zimvie INC. | $51.48 | 2023 | |
| Triad Life Sciences INC. | $40.28 | 2022 | |
| Treace Medical Concepts, INC. | $35.92 | 2023-2024 | |
| Kci USA, INC. | $35.27 | 2019-2020 | |
| Nevro Corp. | $32.91 | 2022-2023 | Senza |
| Spr Therapeutics, INC | $29.82 | 2020 | |
| Abbvie INC. | $28.98 | 2023 | Dalvance |
| Alfasigma USA, INC. | $25.45 | 2021-2022 | |
| Grt US Holding, INC. | $21.53 | 2021-2022 | |
| Nabriva Therapeutics, Plc | $18.21 | 2021 | |
| Zimmer Biomet Holdings, INC. | $18.17 | 2019 | |
| Osiris Therapeutics INC. | $12.78 | 2019 | |
| Zyla Life Sciences, INC. | $11.41 | 2019 | |
| Axogen | $10.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Crabtree listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.